{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:40:05Z","timestamp":1773038405620,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.clml.2022.12.012","type":"journal-article","created":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T02:27:48Z","timestamp":1671848868000},"page":"211-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM Criteria"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0145-2239","authenticated-orcid":false,"given":"Ellen","family":"Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nowell","family":"Fine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4676-2433","authenticated-orcid":false,"given":"Robert","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2386-8817","authenticated-orcid":false,"given":"Christopher","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Tay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Chhibber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Mahe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9294-9437","authenticated-orcid":false,"given":"Victor H.","family":"Jimenez-Zepeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.12.012_bib0001","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.012_bib0002","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.012_bib0003","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","article-title":"The role of diagnosis and clinical follow-up of monoclonal gammopathy of undetermined significance on survival in multiple myeloma","volume":"1","author":"Sigurdardottir","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2022.12.012_bib0004","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/jamaoncol.2015.33","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"1","author":"Kyle","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2022.12.012_bib0005","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.hoc.2014.06.005","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"28","author":"Kyle","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2022.12.012_bib0006","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4065\/mcp.2010.0520","article-title":"Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undertermines significance: implications for recategorizing disease entities in the presence of evolving scientific evidence","volume":"85","author":"Rajkumar","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2022.12.012_bib0007","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.12.012_bib0008","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010 May 15;375(9727):1721-8. 10.1016\/S0140-6736(10)60482-5. Erratum in: Lancet. 2010 Jul 31;376(9738):332. PMID: 20472173; PMCID: PMC2904571.","DOI":"10.1016\/S0140-6736(10)60482-5"},{"key":"10.1016\/j.clml.2022.12.012_bib0009","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","article-title":"Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies","volume":"11","author":"Rognvaldsson","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.12.012_bib0010","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1309\/AJCPR2M4EUYNHLGM","article-title":"Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis?","volume":"131","author":"Abadie","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2022.12.012_sbref0011","series-title":"Proceedings from American Society of Hematololgy, Atlanta, GA","article-title":"Defining new reference intervals for serum free light chains in individuals with reduced kidney function: results of the population-based on icelans screens treats or prevents multiple myeloma (iSTOPMM) study","author":"Long","year":"2021"},{"key":"10.1016\/j.clml.2022.12.012_bib0012","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)","volume":"25","author":"Phull","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.clml.2022.12.012_bib0013","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clml.2022.12.012_bib0014","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1373\/clinchem.2009.126664","article-title":"Screening panels for detection of monoclonal gammopathies","volume":"55","author":"Katzmann","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.clml.2022.12.012_bib0015","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","author":"Hutchison","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clml.2022.12.012_bib0016","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/ki.2011.94","article-title":"The biology of immunoglobulin free light chains and kidney injury","volume":"79","author":"Basnayake","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.clml.2022.12.012_bib0017","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008225","article-title":"Avoiding catastrophe: understanding free light chain testing in the evaluation of ATTR amyloidosis","volume":"14","author":"Witteles","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.clml.2022.12.012_bib0018","doi-asserted-by":"crossref","first-page":"E141","DOI":"10.1002\/ajh.25440","article-title":"Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis","volume":"94","author":"Sidiqi","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.12.012_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hem.V19.1.202217","article-title":"iStopMM: a monumental effort","volume":"19","author":"Hultcrantz","year":"2022","journal-title":"Hematologist"},{"key":"10.1016\/j.clml.2022.12.012_bib0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12170-021-00670-y","article-title":"Racial and ethnic disparities in transthyretin cardiac amyloidosis","volume":"15","author":"Spencer-Bonilla","year":"2021","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"10.1016\/j.clml.2022.12.012_bib0021","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/leu.2011.368","article-title":"Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites","volume":"26","author":"Greenberg","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.12.012_bib0022","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2006","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2022.12.012_bib0023","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2021-148691","article-title":"Free light-chain levels in patients with transthyretin amyloid cardiomyopathy in Attr-ACT","volume":"138","author":"Hoffman","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.12.012_bib0024","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/ki.2014.333","article-title":"The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease","volume":"87","author":"Yadav","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.clml.2022.12.012_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12882-020-01771-3","article-title":"The renal range of the \u03ba\/\u03bb sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease","volume":"21","author":"Molina-And\u00fajar","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.clml.2022.12.012_bib0026","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 2","key":"10.1016\/j.clml.2022.12.012_bib0027","doi-asserted-by":"crossref","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","article-title":"Cardiac amyloidosis","volume":"18","author":"Martinez-Naharro","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.clml.2022.12.012_bib0028","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:08Z","timestamp":1761871268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2152265022017761"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM Criteria","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}